NRX Pharmaceuticals

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NRx Pharmaceuticals reports strong Q1 performance and growth opportunities

NRx Pharmaceuticals made strides in innovation, debt reduction, and financial stability in Q1 2024.
The company's focus on mental health treatments and addressing unmet medical needs shows market relevance.
Challenges include resolving short interest concerns and securing FDA approvals for key drugs.
Opportunities lie in out-licensing, revenue generation, and partnerships for growth and market expansion.

NRx Pharmaceuticals reports progress in financials and scientific breakthroughs

NRx Pharmaceuticals showcased financial and scientific progress, positioning itself for growth and market penetration.
Strategic initiatives like clinic roll-up and commercial targeting demonstrate a proactive approach to market challenges.
While facing transitions and competition, NRx Pharmaceuticals has opportunities for expansion and innovation in psychiatric treatments.
The company's focus on financial stability, product development, and market strategies reflects a comprehensive growth strategy.

NRx Pharmaceuticals reports improved financials and plans for growth

NRx Pharmaceuticals demonstrated improved financial performance and strategic planning in Q3 2024, with reduced losses and enhanced operational efficiency.
The company's focus on innovation, acquisitions, and precision psychiatry clinics highlights a commitment to growth and market leadership.
While facing challenges in revenue recognition and clinic valuations, NRx Pharmaceuticals has opportunities to drive revenue growth and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

First investigational drug for patients with Severe Bipolar Depression and Acute Suicidal Ideation/Behavior, a high unmet medical need Company received Breakthrough Therapy Designation and a Special Protocol Assessment ("SPA") for this trial helping to mitigate risks and accelerate the timing of this NRX-101 development program First trial site has been contracted with others expected in near future, first dosing of patients is expected in early 2023 Company to meet with research analysts and investors in conjunction with the upcoming JP Morgan Healthcare Conference RADNOR, Pa. , Jan. 3, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that its first clinical trial site has been contracted (with others expected in near future) and that first dosing of patients is expected in early 2023.

NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / December 20, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage central nervous system biopharmaceutical company, today announced the close of the definitive settlement agreements to resolve the pending litigation between Relief and NRx Pharmaceuticals' wholly owned subsidiary, NeuroRx, Inc (NeuroRx). Per the terms of the settlement, (i) NeuroRx has transferred to Relief all of the assets it used in the NRx aviptadil development program, including the regulatory filings, patent applications, clinical data, and the formulation of the aviptadil product it was previously developing, (ii) Relief now has the exclusive right and control going forward and the obligation to use commercially reasonable efforts to develop and commercialize an aviptadil product, (iii) Relief has agreed to use commercially reasonable efforts to continue the existing Right to Try Program for aviptadil in the U.S. for at least two years, (iv) Relief will pay NeuroRx milestone payments if it can successfully obtain commercial approval of an aviptadil product (whether for COVID-19 or any other indication), (v) Relief will pay NeuroRx royalties based on a percentage of future sales of an aviptadil product (whether for COVID-19 or any other indication), up to a maximum of $30 million in the aggregate, (vi) NRx and NeuroRx have agreed not to compete in the development of an aviptadil product in the future, and (vii) Relief and NeuroRx have dismissed their pending litigation.

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

Extensive global pharmaceutical leadership experience in clinical development, operations, and medical affairs Focused psychiatry practice expert in PTSD, Affective Disorders and Schizophrenia Proven track record in research as an investigator and academic grant-funded researcher Visiting Scholar  at Stanford University, Center for Precision Mental Health and Wellness Former roles at Boehringer Ingelheim and Pendulum Therapeutics RADNOR, Pa. , Dec. 5, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced the appointment of Carrie M.

NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

RADNOR, Pa. , Dec. 2, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it received written notice on December 1, 2022 from The Nasdaq Stock Market informing NRx Pharmaceuticals that it has regained compliance with the minimum bid price requirement under the Nasdaq Listing Rule 5450(a)(1) (which requires the Company to maintain a minimum closing bid price of $1.00 per share) and the matter is now closed.

NRx Receives Nasdaq Notice of Listing Compliance

Babcock & Wilcox Enterprises

Muscle Maker

Tenaya Therapeutic

Vapotherm Inc

Venus Concept

Insiders and hedge funds are buying these penny stocks before December 2022. The post Penny Stocks To Buy: 6 Insider Picks Before December 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 6 Insider Picks Before December 2022

Insiders and hedge funds are buying these penny stocks in November. The post Penny Stocks To Buy: Insiders & Hedge Funds Like These 3 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: Insiders & Hedge Funds Like These 3

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Suzanne Messere - Investor Relations Stephen Willard - Chief Executive Officer Seth Van Voorhees - Chief Financial Officer and Treasurer Jonathan Javitt - Founder and Chief Scientist Conference Call Participants Vernon Bernadino - H.C. Wainwright Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the NRx Pharmaceuticals Third Quarter 2022 Earnings Conference Call.

NRx Pharmaceuticals, Inc. (NRXP) Q3 2022 Earnings Call Transcript

Completed a technology transfer, submitted a new manufacturing file to the United States ("U.S.") Food and Drug Administration ("FDA"), and released new drug produced with processes designed to support commercial-stage manufacturing of a Phase 3 investigational drug On track to report data from ongoing Phase 2 clinical trial of NRX-101 in patients with bipolar depression with sub-acute suicidal ideation and behavior (SSIB) in 1Q 2023 Company has received numerous partnering inquiries for NRX-101 Plan to initiate registrational Phase 3 clinical trial of NRX-101 in patients with bipolar depression with acute suicidal ideation and behavior (ASIB) by year-end; data readout expected in 3Q 2023 Commenced Phase 2 clinical trial planning of NRX-101 for post-traumatic stress disorder ("PTSD") Ended quarter with $18.2 million in cash and cash equivalents and announced completion of a subsequent unsecured debt financing on November 7, 2022, providing net proceeds of $10.0 million to support the NRx Pharmaceuticals' pipeline of life-saving therapeutics RADNOR, Pa. , Nov. 14, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the third quarter of 2022 and provided a business and clinical update.

NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Adaptimmune Therapeutics

CorMedix

Matterport

Purple Innovation

Analysts say these are penny stocks to buy. Do you agree?

5 Penny Stocks To Buy According To Analysts, Targets Up To 353%

--Company to Host Conference Call November 14, 2022, at 8:00AM ET--- RADNOR, Pa. , Nov. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report third quarter 2022 financial results prior to the market open on November 14, 2022.

NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022

Manufacturing files submitted to U.S. Food and Drug Administration The company has now completed its transition to U.S.-based manufacturing NRX-101 is now manufactured via a commercial-stage process RADNOR, Pa. , Nov. 9, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company, today announced the release of the first batches manufactured in the U.S. of NRX-101, its Phase 3-ready investigational drug, targeting suicidal bipolar depression and with future study plans for post-traumatic stress disorder (PTSD).

NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process

RADNOR, Pa. , Nov. 7, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company, today announced that it has obtained approximately $11 million in unsecured debt financing (the "Note") from Streeterville Capital, LLC, a Utah limited liability company.

NRx Pharmaceuticals Closes $11 Million Unsecured Debt Financing

Company to Present Corporate Update During Investor Conference, Sept. 14, 2022, at 9:00am ET RADNOR, Pa.

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference

Release of an ad hoc announcement pursuant to Art. 53 LR GENEVA and RADNOR, Pa.

RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION

GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / August 22, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx"), today announced that they have agreed to a tentative settlement of their pending litigation. The parties have agreed to work collaboratively to finalize the settlement within the next 30 days.

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation

The stock price of NRx Pharmaceuticals (NRXP) fell by 6.29% in the previous trading session. This is why.

NRx Pharmaceuticals (NRXP) Stock: Why It Fell 6.29%

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Tom Johnson - Investor Relations Stephen Willard - Chief Executive Officer Seth Van Voorhees - Chief Financial Officer & Treasurer Robert Besthof - Head of Operations & Chief Commercial Officer Conference Call Participants Vernon Bernardino - HC Wainwright Operator Good day, and welcome to the NRx Pharmaceuticals Second Quarter 2022 Conference Call. All participants will be in a listen-only mode.

NRx Pharmaceuticals, Inc. (NRXP) CEO Stephen Willard on Q2 2022 Results - Earnings Call Transcript

Company to Host Conference Call and Webcast August 15, 2022, at 8:30am ET RADNOR, Pa. , Aug. 15, 2022  /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the second quarter of 2022 and provided a business and clinical update.

NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise

--Company to Host Conference Call August 15th, 2022, at 8:30AM ET--- RADNOR, Pa. , Aug. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report second quarter 2022 financial results prior to the market open on August 15, 2022.

NRx Pharmaceuticals to Report Second Quarter 2022 Results on August 15, 2022

Extensive experience in Law, Finance, and Management of Public and Private Biotechnology Companies Proven track record of creating value for shareholders National Science Board Presidential Appointee, 2018-2024 Former roles at Federal Deposit Insurance Corporation (FDIC) and E*Trade Financial RADNOR, Pa. , July 13, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP): ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, today announced the appointment of Stephen Willard, as its Chief Executive Officer ("CEO") and a member of the Company's Board of Directors.

NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director

GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (" NRx "), of its collaboration partner with respect to aviptadil, NeuroRx, Inc. (" NeuroRx "), has announced that the U.S. Food and Drug Administration (" FDA ") has declined to issue an Emergency Use Authorization (EUA) for aviptadil for a subgroup of patients that, in addition to aviptadil, also received remdesivir and continued to progress. The related NRx press release can be accessed through the following link.

Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk

Focus is now on NRX-101 for Bipolar Depression with Suicidality RADNOR, Pa. , July 1, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has declined to issue an Emergency Use Authorization (EUA) for ZYESAMI® (aviptadil) for a sub-group of patients that in addition to ZYESAMI®, also received Remdesivir and continued to progress.

FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir

Company to Present Corporate and Psychiatry Franchise Update During Webcast, June 27, 2022, at 7:00am ET  RADNOR, Pa. , June 23, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmaceutical company, today announced its interim Chief Executive Officer, Robert Besthof, and other executive leaders will be presenting a virtual update to the company's business via webcast at the H.C.

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond

RADNOR, Pa. , June 22, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company, is pleased to announce that on June 13, 2022, the plaintiffs in the securities class action lawsuit captioned "Dal Bosco v.

Class Action Suit Against NRx Pharmaceuticals Dismissed

GENEVA, SWITZERLAND / ACCESSWIRE / June 13, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx"), of its collaboration partner with respect to aviptadil, NeuroRx, Inc. ("NeuroRx"), has announced that the U.S. Food and Drug Administration ("FDA") has denied its most recent application seeking Breakthrough Therapy designation ("BTD") for aviptadil. The related NRx press release can be accessed through the following link.

News for NRX Pharmaceuticals Stock (NRXP)